![Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS](https://www.pnas.org/cms/10.1073/pnas.1901734117/asset/3df9a166-9499-4800-a9f7-49e5fac85081/assets/graphic/pnas.1901734117fig01.jpeg)
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties | PNAS
![PDF) Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria PDF) Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria](https://www.researchgate.net/profile/Bhawna-Sirohi/publication/11845605/figure/fig5/AS:271515555987480@1441745761646/Log-rank-comparison-of-overall-survival-of-patients-with-BJ-n-53-IgG-n-153-and_Q320.jpg)
PDF) Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria
![PDF) Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria PDF) Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria](https://www.researchgate.net/profile/Bhawna-Sirohi/publication/11845605/figure/tbl2/AS:667110120386577@1536062855926/Comparison-of-treatment-received-and-response-to-treatment_Q320.jpg)
PDF) Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria
Article: Monoclonal gammopathy with significance: case series and literature review (full text) - Juli 2020 - NJM
![Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-023-06037-y/MediaObjects/41419_2023_6037_Fig5_HTML.png)
Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease
![Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41419-023-06037-y/MediaObjects/41419_2023_6037_Fig1_HTML.png)
Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease
![Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome | Cell Death & Disease](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-023-06037-y/MediaObjects/41419_2023_6037_Fig21_HTML.png)